RxDoctor Payments Data

Jonathan Ross

Optometrist · West Mifflin, PANPI 1538150578

Payments from drug & device makers

$4,280in general payments, 2019–2025

Across 145 payments — averaging $29.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • AbbVie$511
  • Bausch & Lomb Americas Inc.$485
  • Coopervision Inc.$397
  • Oyster Point Pharma, Inc.$232
  • Tarsus Pharmaceuticals, Inc.$191
  • plus $910 from 9 others

What the payments were for

  • Speaking & faculty fees$1453%
  • Travel & lodging$68516%
  • Food & beverage$3,45081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,280 in reported general payments places this provider in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$74,648
Medicare patients
346
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine82$94,280
Cyclosporine98$55,534
XiidraLifitegrast47$37,717
MieboPerfluorohexyloctane/Pf36$26,441
LumiganBimatoprost55$21,244
XdemvyLotilaner12$21,131
VevyeCyclosporine17$12,761
RocklatanNetarsudil Mesylat/Latanoprost18$5,667
VyzultaLatanoprostene Bunod14$4,503
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$3,967
Brimonidine Tartrate40$3,413
Tobradex StTobramycin/Dexamethasone11$2,549
Travoprost12$1,168
Latanoprost133$948
Epinastine Hcl16$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$511$115,523137 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$485$68,66097 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$191$21,13112 claims
Harrow Eye, LLCVevye$31$12,76117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in West Mifflin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →